信迪利单抗联合多西他赛与洛铂方案对复发性食管癌的治疗效果  

Effect of Sintilimab Combined with Docetaxel and Lobaplatin Regimen on Recurrent Esophageal Cancer

作　　者：苗凤真 杜伟 MIAO Fengzhen;DU Wei(Department of Oncology,Xi County Peopled Hospital,Xinyang 464300,China)

机构地区：[1]息县人民医院肿瘤科,河南信阳464300

出　　处：《河南医学研究》2022年第10期1885-1887,共3页Henan Medical Research

摘　　要：目的探讨信迪利单抗联合多西他赛与洛铂(DL)方案在复发性食管癌治疗中的应用价值。方法选取2019年2月至2020年6月息县人民医院收治的72例复发性食管癌患者。根据治疗方式将患者分为对照组和观察组,各36例。对照组患者接受DL方案化疗,观察组患者在对照组基础上联合信迪利单抗治疗。21d为1个治疗周期,两组均连续治疗4个周期。比较两组患者治疗4个周期的总缓解率。记录两组患者治疗期间发生的毒副反应。统计并对比两组患者随访1a期间的生存情况。结果治疗4个周期,观察组总缓解率高于对照组(P<0.05)。治疗期间,两组毒副反应总发生率比较,差异无统计学意义(P>0.05)。随访1a,全部患者均获得随访结果,观察组1a生存率高于对照组(P<0.05)。结论信迪利单抗联合DL方案可提高复发性食管癌的疗效和生存率,且不增加毒副反应。Objective To investigate the value of sintilimab combined with docetaxel and lobaplatin(DL)regimen in the treatment of recurrent esophageal cancer.Methods A total of 72 patients with recurrent esophageal cancer treated in Xi County People's Hospital from February 2019 to June 2020 were selected.According to the treatment methods,the patients were divided into control group and observation group,with 36 cases in each group.The patients in control group were treated with DL regimen chemotherapy,and the patients in observation group were treated with sintilimab on the basis of control group.Twenty-one days was one treatment cycle,and both groups were treated for 4 consecutive cycles.The total remission rate of the two groups after 4 cycles of treatment was compared.The toxic and side effects of the two groups during treatment were recorded.The survival of the two groups during one year of follow-up was counted and compared.Results After 4 cycles of treatment,the total remission rate in observation group was higher than that in control group(P<0.05).During treatment,there was no statistical difference in the total incidence of toxic and side effects between the two groups(P>0.05).All patients gained the follow-up results after 1 year of follow-up.The 1-year survival rate of observation group was higher than that of control group(P<0.05).Conclusion Sindilumab combined with DL regimen can improve the curative effect and survival rate of recurrent esophageal cancer without increasing the side effects.

关 键 词：食管癌 复发 信迪利单抗 多西他赛 洛铂 毒副反应 

分 类 号：R735.1[医药卫生—肿瘤]